Efficacy of levonorgestrel releasing intrauterine system in the treatment of symptomatic adenomyosis: comparison with dienogest
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20252324Keywords:
Adenomyosis, LNG-IUS, Dienogest, Dysmenorrhea, MenorrhagiaAbstract
Background: Adenomyosis is a common, estrogen-dependent, chronic gynecological condition that often presents with dysmenorrhea, menorrhagia, and an enlarged uterus. This study aimed to evaluate and compare the effectiveness of the levonorgestrel-releasing intrauterine system (LNG-IUS) and oral dienogest in the management of symptomatic adenomyosis.
Methods: This randomized controlled trial was conducted in the department of reproductive endocrinology and infertility, Bangabandhu Sheikh Mujib medical university (BSMMU), Dhaka, Bangladesh, from April 2022 to March 2023. In this study, we included 32 women aged 25-45 years diagnosed with symptomatic adenomyosis (menorrhagia and dysmenorrhea) attending the outpatient department of reproductive endocrinology and infertility at BSMMU. Participants were assigned to two treatment groups: One group received LNG-IUS and other group received dienogest.
Results: Baseline demographic and clinical characteristics were similar between the groups. The LNG-IUS group showed a significantly greater reduction in menstrual pain at both 3 months (VAS 1.7±2.9 vs. 4.1±2.8) and 6 months (VAS 0.9±2.5 vs. 3.9±3.0) compared to the dienogest group (p<0.05). Uterine volume decreased more in the LNG-IUS group over time, but the differences were not statistically significant. Regular menstrual flow was significantly more common in the LNG-IUS group at both follow-ups, while heavy bleeding persisted in a notable portion of the dienogest group (p=0.004 and p=0.002, respectively). Hemoglobin levels improved significantly more in the LNG-IUS group by 6 months (100% vs. 57.14%; p=0.017). Although adverse effects were more frequently reported in the dienogest group, the difference was not statistically significant.
Conclusions: This study showed that LNG-IUS was more effective than oral dienogest in reducing pain, improving menstrual bleeding patterns, and increasing hemoglobin levels in women with symptomatic adenomyosis, with a lower incidence of side effects.
Metrics
References
Chen S, Wang J, Sun W, Zhu L, He J, Zhang X. Efficacy of the levonorgestrel-releasing intrauterine device is associated with different subtypes of adenomyosis: a retrospective study. Ann Transl Med. 2020;8(21):1356. DOI: https://doi.org/10.21037/atm-20-3420
Song SY, Lee SY, Kim HY, Park DB, Lee KH, Lee S, et al. Long-term efficacy and feasibility of levonorgestrel-releasing intrauterine device use in patients with adenomyosis. Medicine (Baltimore). 2020;99(22):e20421. DOI: https://doi.org/10.1097/MD.0000000000020421
Rapkin AJ, Nathan L. Pelvic Pain and dysmenorrhea. In: Berek JS, editor. Berek and Novak’s Gynecology. Philadelphia: Lippincott Williams and Wilkins. 2012;481-2.
Cunningham RK, Horrow MM, Smith RJ, Springer J. Adenomyosis: a sonographic diagnosis. Radiographics. 2018;38(5):1576-89. DOI: https://doi.org/10.1148/rg.2018180080
Li JJ, Chung JP, Wang S, Li TC, Duan H. The investigation and management of adenomyosis in women who wish to improve or preserve fertility. Biomed Res Int. 2018;2018:6832685. DOI: https://doi.org/10.1155/2018/6832685
Guo SW, Mao X, Ma Q, Liu X. Dysmenorrhea and its severity are associated with increased uterine contractility and overexpression of oxytocin receptor (OTR) in women with symptomatic adenomyosis. Fertil Steril. 2013;99(1):231-40. DOI: https://doi.org/10.1016/j.fertnstert.2012.08.038
Nie J, Liu X, Guo SW. Immunoreactivity of oxytocin receptor and transient receptor potential vanilloid type 1 and its correlation with dysmenorrhea in adenomyosis. Am J Obstet Gynecol. 2010;202(4):346.e1. DOI: https://doi.org/10.1016/j.ajog.2009.11.035
Mechsner S, Grum B, Gericke C, Loddenkemper C, Dudenhausen JW, Ebert AD. Possible roles of oxytocin receptor and vasopressin-1α receptor in the pathomechanism of dysperistalsis and dysmenorrhea in patients with adenomyosis uteri. Fertil Steril. 2010;94(7):2541-6. DOI: https://doi.org/10.1016/j.fertnstert.2010.03.015
Tremellen K, Russell P. Adenomyosis is a potential cause of recurrent implantation failure during IVF treatment. Aust N Z J Obstet Gynaecol. 2011;51(3):280-3. DOI: https://doi.org/10.1111/j.1479-828X.2010.01276.x
Park DS, Kim ML, Song T, Yun BS, Kim MK, Jun HS, et al. Clinical experiences of the levonorgestrel-releasing intrauterine system in patients with large symptomatic adenomyosis. Taiwan J Obstet Gynecol. 2015;54(4):412-5. DOI: https://doi.org/10.1016/j.tjog.2014.05.009
Peng FS, Wu MY, Yang JH, Chen SU, Ho HN, Yang YS. Insertion of the Mirena intrauterine system for treatment of adenomyosis-associated menorrhagia: a novel method. Taiwan J Obstet Gynecol. 2010;49(2):160-4. DOI: https://doi.org/10.1016/S1028-4559(10)60034-4
Vercellini P, Viganò P, Somigliana E, Fedele L. Endometriosis: pathogenesis and treatment. Nat Rev Endocrinol. 2014;10(5):261-75. DOI: https://doi.org/10.1038/nrendo.2013.255
Irvine GA, Campbell‐Brown MB, Lumsden MA, Heikkilä A, Walker JJ, Cameron IT. Randomised comparative trial of the intrauterine system and norethisterone levonorgestrel for treatment of idiopathic menorrhagia. BJOG. 1998;105(6):592-8. DOI: https://doi.org/10.1111/j.1471-0528.1998.tb10172.x
Abbas AM, Samy A, Atwa K, Ghoneim HM, Lotfy M, Saber Mohammed H, et al. The role of levonorgestrel intra‐uterine system in the management of adenomyosis: A systematic review and meta‐analysis of prospective studies. Acta Obstet Gynecol Scand. 2020;99(5):571-81. DOI: https://doi.org/10.1111/aogs.13798
Zhang P, Song K, Li L, Yukuwa K, Kong B. Efficacy of combined levonorgestrel-releasing intrauterine system with gonadotropin-releasing hormone analog for the treatment of adenomyosis. Med Princ Pract. 2013;22(5):480-3. DOI: https://doi.org/10.1159/000351431
Neriishi K, Hirata T, Fukuda S, Izumi G, Nakazawa A, Yamamoto N, et al. Long‐term dienogest administration in patients with symptomatic adenomyosis. J Obstet Gynaecol Res. 2018;44(8):1439-44. DOI: https://doi.org/10.1111/jog.13674
Yamanaka A, Kimura F, Kishi Y, Takahashi K, Suginami H, Shimizu Y, et al. Progesterone and synthetic progestin, dienogest, induce apoptosis of human primary cultures of adenomyotic stromal cells. Eur J Obstet Gynecol Reprod Biol. 2014;179:170-4. DOI: https://doi.org/10.1016/j.ejogrb.2014.05.031
Schindler AE. Dienogest in long-term treatment of endometriosis. Int J Womens Health. 2011;3:175-84. DOI: https://doi.org/10.2147/IJWH.S5633
Ota I, Taniguchi F, Ota Y, Nagata H, Wada I, Nakaso T, et al. A controlled clinical trial comparing potent progestins, LNG‐IUS and dienogest, for the treatment of women with adenomyosis. Reprod Med Biol. 2021;20(4):427-34. DOI: https://doi.org/10.1002/rmb2.12408
Xu Y, Li L, Yang G. Clinical Efficacy of Dienogest and Levonorgestrel-Releasing Intrauterine System in the Treatment of Adenomyosis. J Clin Nurs Res. 2022;6(5):141-5. DOI: https://doi.org/10.26689/jcnr.v6i5.4213
Yang S, Liu Y, Wen J, Sun Y, Ren F. Clinical Efficacy of Dienogest versus Levonorgestrel-Releasing Intrauterine System for Adenomyosis. Evid Based Complement Alternat Med. 2022;2022:1995472. DOI: https://doi.org/10.1155/2022/1995472
Lee KH, Jung YW, Song SY, Kang BH, Yang JB, Ko YB, et al. Comparison of the efficacy of diegnogest and levonorgestrel‐releasing intrauterine system after laparoscopic surgery for endometriosis. J Obstet Gynaecol Res. 2018;44(9):1779-86. DOI: https://doi.org/10.1111/jog.13703
Park SY, Kim SH, Chae HD, Kim CH, Kang BM. Efficacy and safety of dienogest in patients with endometriosis: a single-center observational study over 12 months. Clin Exp Reprod Med. 2016;43(4):215. DOI: https://doi.org/10.5653/cerm.2016.43.4.215
Downloads
Published
How to Cite
Issue
Section
